Rafi Kabarriti
Expertise in
53
conditions

Dr. Rafi Kabarriti

Radiation Oncology
Brook Avenue At 951 Brook Avenue
951 Brook Avenue, 
Bronx, NY 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
53
conditions
Brook Avenue At 951 Brook Avenue
951 Brook Avenue, 
Bronx, NY 

Overview

Rafi Kabarriti, MD, is a cum laude graduate of Columbia University with a bachelor’s degree in biochemistry and economics.

Dr. Kabarriti is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Anal Cancer, Laryngeal Cancer, Throat Cancer, Cervical Cancer, and Colonoscopy.

He is actively involved in clinical research, co-authoring 95 peer reviewed articles and participating in 6 clinical trials. Dr. Kabarriti is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in NY

Hospital Affiliations

Montefiore Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Archcare
  • MEDICARE SNP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Hamaspik
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Longevity Health Plan
  • MEDICARE SNP
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
MVP Health
  • EPO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
The Wellness Plan Medical Centers
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Brook Avenue At 951 Brook Avenue
951 Brook Avenue, Bronx, NY 10451
Other Locations
Montefiore Medical Center
111 East 210th Street, Bronx, NY 10461

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Fluorouracil, Mitomycin
Study Phase: Phase 2
Risk-Adapted Therapy for HIV-Associated Anal Cancer
Risk-Adapted Therapy for HIV-Associated Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Capecitabine, Fluorouracil, Mitomycin, Nivolumab
Study Phase: Phase 2
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Enrollment Status: Completed
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 5 Less Clinical Trials

95 Total Publications

Determinants of cancer care delays in Kinshasa, Democratic Republic of the Congo (DRC).
Determinants of cancer care delays in Kinshasa, Democratic Republic of the Congo (DRC).
Journal: medRxiv : the preprint server for health sciences
Published: June 05, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (4.2 miles away)
212-639-2000
Languages Spoken:
English

Andreas Rimner is a Radiation Oncologist practicing medicine in New York, New York. Dr. Rimner is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Tissue Biopsy, and Thymectomy.

Expertise in
12
conditions
Dr. Daniel R. Gomez
Radiation Oncology
Expertise in
12
conditions
Dr. Daniel R. Gomez
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (4.2 miles away)
315-275-7348
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Gomez is a Radiation Oncologist practicing medicine in New York, New York. Dr. Gomez is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Mesothelioma. Dr. Gomez is currently accepting new patients.

Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (4.2 miles away)
646-582-9491
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kaled Alektiar is a Radiation Oncologist practicing medicine in New York, New York. Dr. Alektiar is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Adult Soft Tissue Sarcoma, Fibrosarcoma, Cervical Cancer, and Lymphadenectomy. Dr. Alektiar is currently accepting new patients.

Frequently Asked Questions about Dr. Rafi Kabarriti

How do I make an appointment with Dr. Rafi Kabarriti?

You can book an appointment with Dr. Rafi Kabarriti by calling their office at 929-323-3737. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rafi Kabarriti a top-rated expert for Anal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rafi Kabarriti is classified as an Elite expert for Anal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rafi Kabarriti specialize in?

While Dr. Rafi Kabarriti is a Radiation Oncology, they have specific expertise in Anal Cancer, Laryngeal Cancer, and Throat Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Rafi Kabarriti participate in research or clinical trials?

Yes. Dr. Rafi Kabarriti has published 95 articles and abstracts on conditions like Anal Cancer. You can view a list of Dr. Rafi Kabarriti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rafi Kabarriti accept my insurance?

Dr. Rafi Kabarriti accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 929-323-3737 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kabarriti's expertise for a condition
ConditionClose
View All 47 Advanced Conditions
View All 64 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile